Profiling of Kidney Injury Biomarkers in Patients Receiving Cisplatin: Time-dependent Changes in the Absence of Clinical Nephrotoxicity

Blessy George, Xia Wen, Nickie Mercke, Madeleine Gomez, Cindy O'Bryant, Daniel W Bowles, Yichun Hu, Susan L Hogan, Melanie S Joy, Lauren M Aleksunes, Blessy George, Xia Wen, Nickie Mercke, Madeleine Gomez, Cindy O'Bryant, Daniel W Bowles, Yichun Hu, Susan L Hogan, Melanie S Joy, Lauren M Aleksunes

Abstract

The success of cisplatin-containing regimens to treat solid tumors is limited, in part, by nephrotoxicity. In rodents, several urinary proteins have emerged that are sensitive indicators of cisplatin-induced kidney injury. We sought to characterize time-dependent changes in the urinary concentrations of 12 proteins, including kidney injury molecule-1 (KIM-1), calbindin, beta 2-microglobulin (β2M), and trefoil factor 3 (TFF3) after cisplatin therapy. Urine was collected at baseline, 3 days (range, 2-5 days), and 10 days (range, 9-11 days) from 57 patients with solid tumors receiving outpatient cisplatin therapy (≥25 mg/m2 ). Serum creatinine was largely unchanged after cisplatin infusion. However, compared with baseline values, several novel biomarkers were significantly increased in the urine, including β2M, which was threefold higher by day 3 (P < 0.0001). Urinary KIM-1 and TFF3 were elevated twofold by day 10 (P = 0.002 and P = 0.002, respectively), whereas calbindin levels were increased eightfold (P < 0.0001). We report novel time-dependent changes in the urinary excretion of noninvasive markers of subclinical kidney injury after cisplatin treatment.

© 2016 American Society for Clinical Pharmacology and Therapeutics.

Figures

Figure 1. Time-Dependent Changes in Absolute Urinary…
Figure 1. Time-Dependent Changes in Absolute Urinary Concentrations of Protein Biomarkers following Cisplatin Infusion
Urinary protein concentrations were measured using a Bio-Plex assay at baseline (n=57), 3 (range of 2-5, n=50) days and 10 (range of 9-11, n=47) days post cisplatin-infusion during the first or second cycle of chemotherapy. Concentrations were measured in urine supernatants and presented as ng/mL. Scatter plots show individual levels (n=57) and mean ± SD concentration at each time point. Solid lines represent statistically significant differences (p

References

    1. Shord SS, Thompson DM, Krempl GA, Hanigan MH. Effect of concurrent medications on cisplatin-induced nephrotoxicity in patients with head and neck cancer. Anticancer Drugs. 2006;17:207–15.
    1. Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120:c179–84.
    1. Ciarimboli G, et al. Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients. Clin Cancer Res. 2012;18:1101–8.
    1. Vaidya VS, et al. Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nat Biotechnol. 2010;28:478–85.
    1. Sinha V, Vence LM, Salahudeen AK. Urinary tubular protein-based biomarkers in the rodent model of cisplatin nephrotoxicity: a comparative analysis of serum creatinine, renal histology, and urinary KIM-1, NGAL, and NAG in the initiation, maintenance, and recovery phases of acute kidney injury. J Investig Med. 2013;61:564–8.
    1. Pinches M, et al. Evaluation of novel renal biomarkers with a cisplatin model of kidney injury: gender and dosage differences. Toxicol Pathol. 2012;40:522–33.
    1. Dieterle F, et al. Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium. Nat Biotechnol. 2010;28:455–62.
    1. Vijayan A, et al. Clinical Use of the Urine Biomarker [TIMP-2] x [IGFBP7] for Acute Kidney Injury Risk Assessment. Am J Kidney Dis. 2016;68:19–28.
    1. Arthur JM, et al. Evaluation of 32 urine biomarkers to predict the progression of acute kidney injury after cardiac surgery. Kidney Int. 2014;85:431–8.
    1. Hall IE, et al. Risk of poor outcomes with novel and traditional biomarkers at clinical AKI diagnosis. Clinical journal of the American Society of Nephrology : CJASN. 2011;6:2740–9.
    1. Han WK, et al. Urinary biomarkers in the early diagnosis of acute kidney injury. Kidney Int. 2008;73:863–9.
    1. Koyner JL, et al. Urinary biomarkers in the clinical prognosis and early detection of acute kidney injury. Clin J Am Soc Nephrol. 2010;5:2154–65.
    1. Lin HY, et al. Urinary neutrophil gelatinase-associated lipocalin levels predict cisplatin-induced acute kidney injury better than albuminuria or urinary cystatin C levels. Kaohsiung J Med Sci. 2013;29:304–11.
    1. Shinke H, et al. Urinary kidney injury molecule-1 and monocyte chemotactic protein-1 are noninvasive biomarkers of cisplatin-induced nephrotoxicity in lung cancer patients. Cancer Chemother Pharmacol. 2015;76:989–96.
    1. Pavkovic M, et al. Detection of Drug-Induced Acute Kidney Injury in Humans Using Urinary KIM-1, miR-21, -200c, and -423. Toxicol Sci. 2016
    1. Takashi M, Zhu Y, Miyake K, Kato K. Urinary 28-kD calbindin-D as a new marker for damage to distal renal tubules caused by cisplatin-based chemotherapy. Urol Int. 1996;56:174–9.
    1. Group, K.D.I.G.O.K.A.K.I.W. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney inter. 2012;(Suppl 2):1–138.
    1. Madias NE, Harrington JT. Platinum nephrotoxicity. Am J Med. 1978;65:307–14.
    1. Latcha S, Jaimes EA, Patil S, Glezerman IG, Mehta S, Flombaum CD. Long-Term Renal Outcomes after Cisplatin Treatment. Clin J Am Soc Nephrol. 2016;11:1173–9.
    1. Hosohata K, et al. Early prediction of cisplatin-induced nephrotoxicity by urinary vanin-1 in patients with urothelial carcinoma. Toxicology. 2016;359-360:71–5.
    1. Wen J, et al. Aging increases the susceptibility of cisplatin-induced nephrotoxicity. Age (Dordr) 2015;37:112.
    1. Brott DA, Adler SH, Arani R, Lovick SC, Pinches M, Furlong ST. Characterization of renal biomarkers for use in clinical trials: biomarker evaluation in healthy volunteers. Drug Des Devel Ther. 2014;8:227–37.
    1. Tang KW, Toh QC, Teo BW. Normalisation of urinary biomarkers to creatinine for clinical practice and research--when and why. Singapore Med J. 2015;56:7–10.
    1. Mattix HJ, Hsu CY, Shaykevich S, Curhan G. Use of the albumin/creatinine ratio to detect microalbuminuria: implications of sex and race. J Am Soc Nephrol. 2002;13:1034–9.
    1. Ralib AM, et al. Test characteristics of urinary biomarkers depend on quantitation method in acute kidney injury. J Am Soc Nephrol. 2012;23:322–33.
    1. Kabanda A, Vandercam B, Bernard A, Lauwerys R, van Ypersele de Strihou C. Low molecular weight proteinuria in human immunodeficiency virus-infected patients. Am J Kidney Dis. 1996;27:803–8.
    1. Baines RJ, Brunskill NJ. Tubular toxicity of proteinuria. Nat Rev Nephrol. 2011;7:177–80.
    1. Singh A, Satchell SC. Microalbuminuria: causes and implications. Pediatr Nephrol. 2011;26:1957–65.
    1. Ichimura T, et al. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem. 1998;273:4135–42.
    1. Vaidya VS, Ramirez V, Ichimura T, Bobadilla NA, Bonventre JV. Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury. Am J Physiol Renal Physiol. 2006;290:F517–29.
    1. Bailly V, Zhang Z, Meier W, Cate R, Sanicola M, Bonventre JV. Shedding of kidney injury molecule-1, a putative adhesion protein involved in renal regeneration. J Biol Chem. 2002;277:39739–48.
    1. Taupin D, Podolsky DK. Trefoil factors: initiators of mucosal healing. Nat Rev Mol Cell Biol. 2003;4:721–32.
    1. Yu Y, et al. Urinary biomarkers trefoil factor 3 and albumin enable early detection of kidney tubular injury. Nat Biotechnol. 2010;28:470–7.
    1. Lebherz-Eichinger D, et al. Trefoil Factor 1 Excretion Is Increased in Early Stages of Chronic Kidney Disease. PLoS One. 2015;10:e0138312.
    1. Xiao L, Liu YP, Xiao CX, Ren JL, Guleng B. Serum TFF3 may be a pharamcodynamic marker of responses to chemotherapy in gastrointestinal cancers. BMC Clin Pathol. 2014;14:26.
    1. Bredderman PJ, Wasserman RH. Chemical composition, affinity for calcium, and some related properties of the vitamin D dependent calcium-binding protein. Biochemistry. 1974;13:1687–94.
    1. Sohn SJ, et al. In vitro evaluation of biomarkers for cisplatin-induced nephrotoxicity using HK-2 human kidney epithelial cells. Toxicol Lett. 2013;217:235–42.
    1. Peres LA, et al. Evaluation of the cisplatin nephrotoxicity using the urinary neutrophil gelatinase-associated lipocalin (NGAL) in patients with head and neck cancer. J Bras Nefrol. 2014;36:280–8.
    1. Won AJ, et al. Discovery of urinary metabolomic biomarkers for early detection of acute kidney injury. Mol Biosyst. 2016;12:133–44.
    1. Schmidt-Ott KM, et al. Dual action of neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol. 2007;18:407–13.
    1. Xie Y, Sakatsume M, Nishi S, Narita I, Arakawa M, Gejyo F. Expression, roles, receptors, and regulation of osteopontin in the kidney. Kidney Int. 2001;60:1645–57.
    1. Arunkumar PA, Viswanatha GL, Radheshyam N, Mukund H, Belliyappa MS. Science behind cisplatin-induced nephrotoxicity in humans: a clinical study. Asian Pac J Trop Biomed. 2012;2:640–4.
    1. Blaine J, Chonchol M, Levi M. Renal control of calcium, phosphate, and magnesium homeostasis. Clin J Am Soc Nephrol. 2015;10:1257–72.
    1. Glaudemans B, Knoers NV, Hoenderop JG, Bindels RJ. New molecular players facilitating Mg(2+) reabsorption in the distal convoluted tubule. Kidney Int. 2010;77:17–22.
    1. He H, et al. Urinary interleukin-18 as an early indicator to predict contrast-induced nephropathy in patients undergoing percutaneous coronary intervention. Exp Ther Med. 2014;8:1263–6.
    1. Katholi RE, et al. Oxygen free radicals and contrast nephropathy. Am J Kidney Dis. 1998;32:64–71.
    1. de Jongh FE, et al. Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J Clin Oncol. 2001;19:3733–9.
    1. Levey AS, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247–54.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere